Clinical presentation and diagnosis of myocarditis

Heart

Volumn 101, Issue 16, 2015, Pages 1332-1344

  Caforio, Alida L P ^a   Marcolongo, Renzo ^a   Basso, Cristina ^a   Iliceto, Sabino ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; FLUORODEOXYGLUCOSE; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; IMMUNOGLOBULIN G ANTIBODY; PENTRAXIN 3; TROPONIN I; TROPONIN T;

ARTICLE; CARDIOGENIC SHOCK; CARDIOVASCULAR MAGNETIC RESONANCE; CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FAINTNESS; FEVER; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE BIOPSY; HEART PALPITATION; HUMAN; MALAISE; MEDICAL HISTORY; POSITRON EMISSION TOMOGRAPHY; PR INTERVAL; PRIORITY JOURNAL; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SEROLOGY; ST SEGMENT ELEVATION; SUDDEN CARDIAC DEATH; THORAX PAIN; VIRUS MYOCARDITIS; BIOPSY; BLOOD; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; DISEASE MANAGEMENT; ELECTROCARDIOGRAPHY; HEART MUSCLE; MYOCARDITIS; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES;

BIOLOGICAL MARKERS; BIOPSY; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDITIS; MYOCARDIUM;

EID: 84941651364     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-306363     Document Type: Article

References (105)

1. Richardson P, McKenna WJ, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996;93:841-2.
2. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial disease. Eur Heart J 2007;29:270-6. Current classification of the cardiomyopathies endorsed by the ESC Working group on myocardial and pericardial disease.
3. Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management and therapy of myocarditis. A Position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636-48. Expert consensus paper endorsed by the ESC Working group on myocardial and pericardial disease that introduces new diagnostic criteria for clinically suspected and definite myocarditis and provides clinical guidance on work-up, management and therapy. It includes suggested technical requirements for immunohistochemistry and molecular analysis.
4. Aretz HT, Billingham ME, Edwards WE, et al. Myocarditis: a histopathologic definition and classification. Am J Cardiol Pathol 1985;1:1-10. Historical paper setting up the Dallas histological criteria for myocarditis.
5. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of cardiomyopathies. An American Heart Association Scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; quality of Care and Outcome research and Functional Genomics and Translational Biology Interdisciplinary Working Groups: and Council on Epidemiology and Prevention. Circulation 2006;113:1807-16.
6. Leone O, Veinot JP, Angelini A, et al. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 2012;21:245-74. Recent landmark pathologists' consensus paper on endomyocardial biopsy and its diagnostic role, technical requirements, strengths and limitations. It includes new immunohistological and molecular virological analysis applied to endomyocardial biopsy.
7. Caforio AL, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007;28:1326-33.
8. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995;333:269-75.
9. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 2007;50:1914-31. Scientific statement on the role of endomyocardial biopsy in cardiovascular disease. It does not include indications in relation to new immunohistological and molecular virological analysis applied to endomyocardial biopsy.
10. Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med 2010;362:1248-9.
11. Maisch B, Schönian U, Crombach M, et al. Cytomegalovirus associated inflammatory heart muscle disease. Scan J Infect Dis 1993;88:135-48.
12. Martin AB, Webber S, Fricker FJ, et al. Acute myocarditis, rapid diagnosis by PCR in children. Circulation 1994;90:330-9.
13. Pankuweit S, Moll R, Baandrup U, et al. Prevalence of Parvovirus B 19 genome in endomyocardial biopsy specimen. Hum Pathol 2003;34:80-6.
14. Kühl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 2005;111:887-93.
15. Kühl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005;112:1965-70. First report which describes the association of progressive cardiac dysfunction with viral persistence at a follow-up endomyocardial biopsy.
16. Bowles NE, Ni J, Kearney DL, et al. Detection of viruses in myocardial tissues by polymerase chain reaction: evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003;42:466-72. First report describing a high prevalence of adenovirus in paediatric biopsy-proven myocarditis.
17. Schultheiss HP, Kühl U, Cooper LT. The management of myocarditis. Eur Heart J 2011;32:2616-25.
18. Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008;118:639-48. This study shows that immunohistochemical findings on endomyocardial biopsy predict a bad outcome in myocarditis.
19. Friedrich G, Sechtem U, Schulz-Menger J, et al. International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 2009;53:1475-87. Consensus paper with the first description and introduction of the Lake Louise criteria for the CMR diagnosis of myocarditis that are currently used.
20. Francone M, Chimenti C, Galea N, et al. CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis. JACC Cardiovasc Imaging 2014;7:254-63. Interesting paper showing that when assessed in biopsy-proven myocarditis CMR has lower sensitivity, even using Lake Louise criteria, than that reported in ref. 19 according to the type of clinical presentation, being lower in heart failure and in arrhythmic than in infarct-like presentations. Thus, according to the authors' findings a negative CMR does not always rule out biopsy-proven acute myocarditis and should not preclude the use of endomyocardial biopsy in clinically suspected cases. This observation is in keeping with ESC 2013 Task Force recommendations set in ref. 3.
21. Röttgen R, Christiani R, Freyhardt P, et al. Magnetic resonance imaging findings in acute myocarditis and correlation with immunohistological parameters. Eur Radiol 2011;21:1259-66. Paper showing, similar to ref. 20, that CMR findings may be less sensitive than endomyocardial biopsy for myocarditis diagnosis.
22. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004;109:1250-8.
23. Rose NR. Myocarditis: infection versus autoimmunity. J Clin Immunol 2009;29:730-7.
24. Caforio ALP, Marcolongo R, Jahns R, et al. Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and treatment. Heart Fail Rev 2013;18; 715-32. Recent review focusing on immune-mediated myocarditis from clinical presentation to treatment.
25. Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine 2009;88:236-43.
26. Oliveira GH, Seward JB, Tsang TS, et al. Echocardiographic findings in patients with Wegener granulomatosis. Mayo Clin Proc 2005;80:1435-40.
27. Frustaci A, Gentiloni N, Caldarulo M. Acute myocarditis and left ventricular aneurism as presentations of systemic lupus erythematosus. Chest 1996;109:282-4.
28. Dankó K, Ponyi A, Constantin T, et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 2004;83:35-42.
29. Courand PY, Croisille P, Khouatra C, et al. Churg-Strauss syndrome presenting with acute myocarditis and cardiogenic shock. Heart Lung Circ 2012;21:178-81.
30. Pankuweit S, Klingel K. Viral myocarditis: from experimental models to molecular diagnosis in patients. Heart Fail Rev 2013;18:683-702. Recent extensive review on viral myocarditis from experimental models to clinical studies dealing with molecular diagnosis.
31. Bock CT, Düchting A, Utta F, et al. Molecular phenotypes of human parvovirus B19 in patients with myocarditis. World J Cardiol 2014;6:183-95.
32. Liu P, Martino T, Opavsky MA, et al. Viral myocarditis: balance between viral infection and immune response. Can J Cardiol 1996;12:935-43.
33. Huber SA, Gauntt CJ, Sakkinen P. Enteroviruses and myocarditis: viral pathogenesis through replication, cytokine induction, and immunopathogenicity. Adv Virus Res 1999;51:35-68.
34. Klingel K, Hohenadl C, Canu A, et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci USA 1992;; 89:314-18.
35. MacLellan RW, Lusis AJ. Dilated cardiomyopathy: learning to live with yourself. Nat Med 2003;9:1455-6.
36. Rose NR. Viral damage or 'molecular mimicry'-placing the blame in myocarditis. Nature Med 2000;6:631-2.
37. Neu N, Rose NR, Beisel KW, et al. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol 1987;139:3630-6.
38. Smith SC, Allen PM. Myosin-induced myocarditis is a T cell-mediated disease. J Immunol 1991;147:2141-7.
39. Li Y, Heuser JS, Cunningham LC, et al. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 2006;177:8234-40.
40. Kodama M, Hanawa H, Saeki M, et al. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 1994;75:278-84.
41. Taneja V, Behrens M, Cooper LT, et al. Spontaneous myocarditis mimicking human disease occurs in the presence of an appropriate MHC and non-MHC background in transgenic mice. J Mol Cell Cardiol 2007;42:1054-64.
42. Elliott JF, Liu J, Yuan ZN, et al. Autoimmune cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic Abeta knockout NOD mice. Proc Natl Acad Sci USA 2003;100:13447-52.
43. Satoh M, Shimoda Y, Maesawa C, et al. MMyD88 signaling controls autoimmune myocarditis induction. Circulation 2006;113:258-65.
44. Lv H, Havari E, Pinto S, et al. Impaired thymic tolerance to a-myosin directs autoimmunity to the heart in mice and humans. J Clin Invest 2011;121:1561-73.
45. Guler ML, Ligons DL, Wang Y, et al. Two autoimmune diabetes loci influencing T cell apoptosis control susceptibility to experimental autoimmune myocarditis. J Immunol 2005;174:2167-73.
46. Ono M, Shimizu J, Miyachi Y, et al. Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-related proteinhigh, Foxp3-expressing CD25+ and CD25-regulatory T cells. J Immunol 2006;176:4748-56.
47. Caforio ALP, Tona F, Bottaro S, et al. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity 2008;41:35-45.
48. Caforio ALP, Keeling PJ, Zachara E, et al. Evidence from family studies for autoimmunity in dilated cardiomyopathy. Lancet 1994;344:773-7. First report showing increased frequency of serum cardiac-specific autoantibodies in apparently symptom-free relatives of patients with dilated cardiomyopathy.
49. Caforio ALP, Mahon NG, Baig KM, et al. Prospective familial assessment in dilated cardiomyopathy. Cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation 2007;115:76-83. First prospective follow-up study in relatives of dilated cardiomyopathy patients showing that a positive serum cardiac autoantibody test at baseline predicts development of dilated cardiomyopathy at 5-year follow-up in subjects with and without minor echocardiographic abnormalities at baseline. This study shows that immune-mediated dilated cardiomyopathy has a long pre-clinical phase and that the autoimmune serology test provides an non-invasive marker of pre-clinical disease.
50. Limas CJ, Iakovis P, Anyfantakis A, et al. Familial clustering of autoimmune diseases in patients with dilated cardiomyopathy. Am J Cardiol 2004;93:1189-91.
51. Meder B, Rühle F, Weis T, et al. A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. Eur Heart J. 2014;35:1069-77. Recent landmark large multicenter European genome-wide association study showing that, without a pre-specified hypothesis, HLA is a risk locus for dilated cardiomyopathy, in keeping with the autoimmune paradigm.
52. Mahon NG, Madden B, Caforio ALP, et al. Immunohistochemical evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. J Am Coll Cardiol 2002;39:455-62. Paper showing that apparently healthy relatives of patients with dilated cardiomyopathy have features of immune activation at endomyocardial biopsy at a very early, pre-clinical stage, and that dilated cardiomyopathy is the end result of a subtle long-lasting myocardial inflammatory process in genetically predisposed subjects.
53. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy. Two-year follow-up results. Circulation 2001;104:39-45.
54. Caforio AL, Angelini A, Blank M, et al. Passive transfer of affinity-purified anti-heart autoantibodies (AHA) from sera of patients with myocarditis induces experimental myocarditis in mice. Int J Cardiol 2015;179:166-77. Recent study proving new evidence by classical passive transfer experiment for direct pathogenic role of cardiac autoantibodies in human myocarditis.
55. Warraich RS, Griffiths E, Falconar A, et al. Human cardiac myosin autoantibodies impair myocyte contractility: a cause-and-effect relationship. FASEB J 2006;20:651-60.
56. Cooper LT Jr, Hare JM, Tazelaar HD, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008;102:1535-9. Paper showing the usefulness of intensive immunosuppression for giant cell myocarditis.
57. Caforio ALP, Bonifacio E, Stewart JT, et al. Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol 1990;15:1527-34.
58. Caforio ALP, Goldman JH, Haven AJ, et al. Circulating cardiac autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. Eur Heart J 1997;18:270-5.
59. Caforio ALP, Grazzini M, Mann JM, et al. Identification of a and ß cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 1992;85:1734-42. Paper showing that cardiac-specific autoantibodies in patients with dilated cardiomyopathy, similar to the murine model of experimental autoimmune myocarditis, recognise a and ß cardiac myosin heavy chain isoforms as major autoantigens.
60. Lauer B, Schannwell M, Kuhl U, et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000;35:11-18.
61. Wallukat G, Morwinski M, Kowal K, et al. Antibodies against the ß-adrenergic receptor in human myocarditis and dilated cardiomyopathy: ß-adrenergic agonism without desensitization. Eur Heart J 1991;12(Suppl D):178-81.
62. Magnusson Y, Wallukat G, Waagstein F, et al. Autoimmunity in idiopathic dilated cardiomyopathy: characterization of antibodies against the ß1-adrenoceptor with positive chronotropic effect. Circulation 1994;89:2760-7. Paper showing that antibodies against the ß1-adrenoceptor, another relevant autoantigen in dilated cardiomyopathy, may have functional positive chronotropic effect.
63. Muller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000;101:385-91. Paper showing for the first time the feasibility of immunoadsorption in dilated cardiomyopathy patients to eliminate potentially cardiotoxic cardiac autoantibodies.
64. Staudt A, Bohm M, Knebel F, et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 2002;106:2448-53.
65. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001;291:319-22.
66. Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003;9:1477-83. Paper showing that cardiac autoantibodies against troponin I are responsible for the development of dilated cardiomyopathy in PD-1-deficient mice, suggesting that in a genetically predisposed animal dilated cardiomyopathy is an autoantibody-mediated disease.
67. Schultheiss HP, Ulrich G, Janda I, et al. Antibody mediated enhancement of calcium permeability in cardiac myocytes. J Exp Med 1988;168:2105-19.
68. Jahns R, Boivin V, Hein L, et al. Direct evidence for a ß1-adrenergic receptor directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004;113:1419-29. Study showing that in another experimental model also antibodies against ß1-adrenergic receptor are responsible for autoimmune dilated cardiomyopathy.
69. Omerovic E, Bollano E, Anderson B, et al. Induction of cardiomyopathy in severe combined immunodeficiency mice by lymphocytes from patients with idiopathic dilated cardiomyopathy. Autoimmunity 2000;32:271-80.
70. Fu LX, Magnusson Y, Bergh CH, et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1993;91:1964-8.
71. Fu LXM, Schulze W, Wallukat G, et al. A synthetic peptide corresponding to the second extracellular loop of the human M2 acetylcholine receptor induces pharmacological and morphological changes in cardiomyocytes by active immunization after 6 months in rabbits. Clin Immunol Immunopathol 1996;78:203-7.
72. Nikolaev VO, Boivin V, Störk S, et al. A novel fluorescent method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol 2007;50:423-31.
73. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009;30:1995-02. First randomised monocentric study showing the efficacy of immunosuppressive therapy with azathioprine and steroids in patients with virus-negative inflammatory cardiomyopathy.
74. Maisch B, Deeg P, Liebau G, et al. Diagnostic relevance of humoral and cytotoxic immune reactions in primary and secondary dilated cardiomyopathy. Am J Cardiol 1983;52:1072-8.
75. Christ T, Wettwer E, Dobrev D, et al. Autoantibodies against the beta1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol 2001;33:1515-25. Study demonstrating functional activity of autoantibodies against the beta1 adrenoceptor from patients with dilated cardiomyopathy in vitro.
76. Staudt Y, Mobini R, Fu M, et al. Beta1-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharmacol 2003;466:1-6.
77. Trimpert C, Herda LR, Eckerle LG, et al. Immunoadsorption in dilated cardiomyopathy: long-term reduction of cardiodepressant antibodies. Eur J Clin Invest 2010;40:685-91.
78. Schulze K, Becker BF, Schauer R, et al. Antibodies to ADP-ATP carrier-an autoantigen in myocarditis and dilated cardiomyopathy-impair cardiac function. Circulation 1990;81:959-69.
79. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993;14:426-8. Landmark study setting new diagnostic criteria for defining autoimmune diseases, with a modification of historical Witebsky's postulates.
80. Lowe CE, Cooper JD, Brusko T, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate a polymorphism in the IL2RA region in Type 1 diabetes. Nature genetics 2007;39:1074-82.
81. Jin B, Ni H, Geshang Q, et al. HLA-DR4 antigen and idiopathic dilated cardiomyopathy susceptibility: a meta-analysis involving 11, 761 subjects. Tissue Antigens 2011;77:107-11. Recent meta-analysis suggesting an association of HLA-DR4 antigen and dilated cardiomyopathy.
82. Kuhl U, Pauschinger M, Bock T, et al. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation 2003;108:945-50. Important study showing the association of parvovirus B19 infection, virus which infects endothelial cells, and myocarditis with pseudo-infarct presentation.
83. Yilmaz A, Mahrholdt H, Athanasiadis A, et al. Coronary vasospasm as the underlying cause of chest pain in patients with PVB19 myocarditis. Heart 2008;94:1456-63. Interesting study suggesting that parvovirus B19, which infects cardiac endothelial cells, in patients with myocarditis and pseudo-infarct presentation may induce coronary vasospasm and consequently chest pain symptoms.
84. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol 2011;4:303-9. Important study describing an unexpectedly high frequency of cardiac sarcoidosis and giant cell myocarditis as causes of unexplained atrioventricular block in young and middle-aged adults, suggesting that these two potentially lethal but treatable forms of myocarditis, regarded to be rare, may be under-recognised.
85. Caforio ALP, Tona F, Vinci A, et al. Acute biopsy-proven lymphocytic myocarditis mimicking Takotsubo cardiomyopathy. Eur J Heart Fail 2009;11:428-31.
86. McCarthy RE, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000;342:690-5.
87. Felker GM, Boehmer JP, Hruban RH, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 2000;36:227-32.
88. Pinamonti B, Alberti E, Cigalotto A, et al. Echocardiographic findings in myocarditis. Am J Cardiol 1988;62:285-91.
89. Sherif HM, Saraste A, Nekolla SG, et al. Molecular imaging of early avß3 integrin expression predicts long-term left-ventricle remodeling after myocardial infarction in rats. J Nucl Med 2012;53:318-23.
90. Blankstein R, Osborne M, Naya M, et al. Cardiac Positron Emission Tomography Enhances Prognostic Assessments of Patients With Suspected Cardiac Sarcoidosis. J Am Coll Cardiol 2014;63:329-36.
91. Baccouche H, Mahrholdt H, Meinhardt G, et al. Diagnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial biopsy in troponin-positive patients without coronary artery disease. Eur Heart J 2009;30:2869-79. Important study describing the higher yield of etiological diagnosis in patients with myocardial infarction and normal coronary arteries using both CMR and endomyocardial biopsy.
92. Yilmaz A, Kindermann I, Kindermann M, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 2010;122:900-9.
93. Holzmann M, Nicko A, Kühl U, et al. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation 2008;118:1722-8.
94. Basso C, Calabrese F, Angelini A, et al. Classification and histological, immunohistochemical, and molecular diagnosis of inflammatory myocardial disease. Heart Fail Rev 2013;18:673-81.
95. Mahfoud F, Gärtner B, Kindermann M, et al. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J 2011;32:897-03. Important study reporting the lack of correlation between viral serology and biopsy-proven viral myocarditis. This study has had an impact on the recommendations by the ESC Task Force (ref 3) in relation to application of viral serology in clinically suspected myocarditis. It is not recommended any more in all patients, but only in selected cases (see text).
96. Costello JM, Alexander ME, Greco KM, et al. Lyme carditis in children: presentation, predictive factors, and clinical course. Pediatrics 2009;123:e835-41.
97. Marin-Neto JA, Cuhna-Neto E, Maciel BC, et al. Pathogenesis of chronic Chagas heart disease. Circulation 2007;115:1109-23.
98. Spina GS, Sampaio RO, Branco CE, et al. Incidental histological diagnosis of acute rheumatic myocarditis: case report and review of the literature. Front Pediatr 2014;2:126.
99. Foerster SR, Canter CE, Cinar A, et al. Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood an outcomes study from the Pediatric Cardiomyopathy Registry. Circ Heart Fail 2010;3:689-97.
100. Saji T, Matsuura H, Hasegawa K, et al. Comparison of the clinical presentation, treatment, and outcome of fulminant and acute myocarditis in children. Circ J 2012;76:1222-8.
101. Ghelani SJ, Spaeder MC, Pastor W, et al. Demographics, trends, and outcomes in pediatric acute myocarditis in the United States, 2006 to 2011. Circ Cardiovasc Qual Outcomes 2012;5:622-7.
102. Hill KD, Atkinson JB, Doyle TP, et al. Routine performance of endomyocardial biopsy decreases the incidence of orthotopic heart transplant for myocarditis. J Heart Lung Transplant 2009;28:1261-6.
103. Japanese Circulation Society (JCS) Joint Working group. Guidelines for diagnosis and treatment of myocarditis. Circ J 2011;75:734-43. One of the few recent Cardiology Society guidelines for myocarditis, issued by the Japanese Circulation Society.
104. Martino TA, Liu P, Sole MJ. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ Res 1994;74:182-8.
105. Kuhl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003;107:2793-8. Single centre experience on the application of interferon-beta treatment for biopsy-proven enteroviral persistence in inflammatory cardiomyopathy, describing virus clearance and improvement of left ventricular function.